What is Immix Biopharma, Inc.'s stock issuance proceeds?

Immix Biopharma, Inc. (IMMX) reported stock issuance proceeds of $33.53K in Q1 2026.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Immix Biopharma, Inc. IMMX Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Nuvectis Pharma, Inc.NVCT

$3.95M+339%

Allogene TherapeuticsALLO

$450K-95.5%

RegenxbioRGNX

$146K-2.7%

Kyverna Therapeutics, Inc.KYTX

$243K+8,000%

XencorXNCR

$950K-68.1%

ImmunomeIMNM

$229K+7.5%

Other financials

Income statement

See full

Operating income-$10.8M-131%

Net income-$10.1M-122%

EPS (diluted)-$0.18-20.0%

Balance sheet

See full

Cash & equivalents$79.3M+398%

Total debt$1.0M-2.0%

Total equity$84.4M+779%

Total assets$95.8M+382%

Cash flow

See full

Operating cash flow-$9.8M-483%

CapEx$32.5K-52.0%

Free cash flow-$9.9M-462%

Valuation

See full

Market cap$691.97M+1,008%

Enterprise value$613.75M+1,190%

Returns & leverage

See full

Return on equity-74.4%-18.6pp

Debt / equity0×-0.1×

Current ratio8.8×+7.0×

Where this comes from

Reported directly by Immix Biopharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immix Biopharma, Inc.'s stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Immix Biopharma, Inc.'s stock issuance proceeds?: Immix Biopharma, Inc. (IMMX) reported stock issuance proceeds of $33.53K in Q1 2026.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.